ClinicalTrials.gg
CompletedNCT02414854Updated Oct 23, 2018Results posted

Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)

A Phase 3 interventional study of Dupilumab and Placebo in Asthma, sponsored by Sanofi. Completed at 389 sites in 22 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-10-23.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,902
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 31 studies testing dupilumab in Asthma — 7 open to participants now, 12 under way, 2 of them phase 3. dupilumab · Asthma.

Enrollment
2nd of 31
1,902 · median 120
Started
2015
with 1 other
Phase 3
11 of 31
2 open now
Registered
4th of 31
by date
Lead sponsor
15 of 31
Sanofi

Among the 31 studies testing dupilumab in Asthma, this one is the 2nd largest by enrollment, is one of 2 that started in 2015, is one of 11 in phase 3, and was the 4th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 31 studies testing dupilumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing dupilumab in Asthma, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the efficacy of dupilumab (SAR231893 / REGN668) in participants with persistent asthma.

Secondary Objectives:

  • To evaluate the safety and tolerability of dupilumab.
  • To evaluate the effect of dupilumab on improving participant-reported outcomes including health-related quality of life.
  • To evaluate dupilumab systemic exposure and incidence of anti-drug antibodies.
Read the detailed description

The total duration of study period for each participant is 67 to 69 weeks, including a screening period of 3 to 5 weeks, treatment period of 52 weeks, and post-treatment follow-up period of 12 weeks.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Adults and adolescent participants with a physician diagnosis of asthma for ≥12 months, based on the Global Initiative for Asthma (GINA) 2014 Guidelines and the following criteria:

a) Existing treatment with medium to high dose ICS (≥250 mcg of fluticasone propionate twice daily or equipotent ICS daily dosage to a maximum of 2000 mcg/day of fluticasone propionate or equivalent) in combination with a second controller (eg, long-acting beta agonist, leukotriene receptor antagonist) for at least 3 months with a stable dose ≥1 month prior to Visit 1.

i) Note for Japan: for participants aged 18 years and older, ICS must be on ≥200 mcg of fluticasone propionate twice daily or equivalent; for participants aged 12 to 17 years, ICS must be ≥100 mcg of fluticasone propionate twice daily or equivalent).

ii) Participants requiring a third controller for their asthma will be considered eligible for this study, and it should also be used for at least 3 months with a stable dose ≥1 month prior to Visit 1.

Exclusion criteria

Exclusion criteria:

  • Participants \<12 years of age or the minimum legal age for adolescents in the country of the investigative site, whichever is higher (For those countries where local regulations permit enrollment of adults only, participant recruitment will be restricted to those who are ≥18 years of age).
  • Weight is less than 30 kilograms.
  • or other lung diseases (eg, idiopathic pulmonary fibrosis, Churg-Strauss Syndrome, etc) which may impair lung function.
  • A participant who experiences a severe asthma exacerbation (defined as a deterioration of asthma that results in emergency treatment, hospitalization due to asthma, or treatment with systemic at any time from 1 month prior to the Screening Visit up to and including the Baseline Visit).
  • Evidence of lung disease(s) other than asthma, either clinical evidence or imaging (Chest X-ray, CT, MRI) within 12 months of Visit 1 or at the screening visit, as per local standard of care.
  • Note for Japan: According to the request from the health authority, chest X-ray should be performed at screening visit if there is no chest imaging (Chest X-ray, computed tomography [CT], magnetic resonance imaging [MRI]) available within 3 months prior to screening to exclude participants with suspected active or untreated latent tuberculosis.
  • Current smoker or cessation of smoking within 6 months prior to Visit 1.
  • Previous smoker with a smoking history >10 pack-years.
  • Comorbid disease that might interfere with the evaluation of Medicinal Product.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,902 participants (actual)

Study arms

  • Placebo comparator
    Placebo (for Dupilumab 200 mg) q2w

    2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection every 2 weeks (q2w) from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.

    Drug: Placebo · Drug: Inhaled corticosteroid (ICS) therapy · Drug: Albuterol/Salbutamol · Drug: Levalbuterol/Levosalbutamol

  • Experimental
    Dupilumab 200 mg q2w

    2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.

    Drug: Dupilumab · Drug: Inhaled corticosteroid (ICS) therapy · Drug: Albuterol/Salbutamol · Drug: Levalbuterol/Levosalbutamol

  • Placebo comparator
    Placebo (for Dupilumab 300 mg) q2w

    2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.

    Drug: Placebo · Drug: Inhaled corticosteroid (ICS) therapy · Drug: Albuterol/Salbutamol · Drug: Levalbuterol/Levosalbutamol

  • Experimental
    Dupilumab 300 mg q2w

    2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines . Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.

    Drug: Dupilumab · Drug: Inhaled corticosteroid (ICS) therapy · Drug: Albuterol/Salbutamol · Drug: Levalbuterol/Levosalbutamol

Interventions

  • Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.

    Also known as: SAR231893, REGN668

  • DrugPlacebo

    Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.

  • DrugInhaled corticosteroid (ICS) therapy

    Oral inhalation, stable dose (medium or high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy)

  • DrugAlbuterol/Salbutamol

    Drug page: Albuterol

    Oral inhalation as needed

  • DrugLevalbuterol/Levosalbutamol

    Drug page: Levalbuterol

    Oral inhalation as needed

06

What researchers measure

Primary outcomes

  1. Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: Intent-to-Treat (ITT) Population

    A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.

    Time frame: Baseline to Week 52

  2. Absolute Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12: ITT Population

    FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population

    FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

    Time frame: Baseline, Week 12

  2. Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil >=0.15 Giga/L

    A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.

    Time frame: Baseline to Week 52

  3. Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.15 Giga/L

    FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

    Time frame: Baseline, Week 12

  4. Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil >=0.3 Giga/L

    A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.

    Time frame: Baseline to Week 52

  5. Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.3 Giga/L

    FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

    Time frame: Baseline, Week 12

  6. Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil <0.3 Giga/L

    A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.

    Time frame: Baseline to Week 52

  7. Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With High Dose ICS at Baseline

    A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.

    Time frame: Baseline to Week 52

  8. Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With High Dose ICS at Baseline

    FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

    Time frame: Baseline, Week 12

  9. Change From Baseline in Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ [S]) Self-Administered Global Score at Week 24: ITT Population

    The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.

    Time frame: Baseline, Week 24

  10. Change From Baseline in AQLQ (S) Self- Administered Global Score at Week 24: ITT Population With Baseline Eosinophil >=0.3 Giga/L

    The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.

    Time frame: Baseline, Week 24

  11. Change From Baseline in Asthma Control Questionnaire 5-item Version (ACQ-5) Score at Week 24: ITT Population

    The ACQ-5 has 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.

    Time frame: Baseline, Week 24

  12. Annualized Rate of Severe Exacerbation Events Resulting in Hospitalization or Emergency Room Visit During The 52-Week Treatment Period: ITT Population

    A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations (resulted hospitalization or emergency room visit) that occurred during the treatment period divided by the total number of participant-years treated.

    Time frame: Baseline to Week 52

  13. Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil <0.3 Giga/L

    FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

    Time frame: Baseline, Week 12

  14. Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.3 Giga/L

    FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

    Time frame: Baseline, Week 12

  15. Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With High Dose ICS at Baseline

    FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

    Time frame: Baseline, Week 12

  16. Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.15 Giga/L

    FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

    Time frame: Baseline, Week 12

  17. Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 24, 36, and 52: ITT Population

    FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

    Time frame: Baseline, Weeks 2, 4, 8, 24, 36, and 52

  18. Percent Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 24, 36, and 52: ITT Population

    FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

    Time frame: Baseline, Weeks 2, 4, 8, 24, 36, and 52

  19. Change From Baseline in Percent Predicted FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population

    FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52

  20. Change From Baseline in Morning (AM)/Evening (PM) Peak Expiratory Flow (PEF) at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population

    The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at home (morning and evening) while sitting or standing prior to using any medication (if needed) for asthma.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52

  21. Change From Baseline in Forced Vital Capacity (FVC) at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population

    FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC is the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52

  22. Change From Baseline in Forced Expiratory Flow (FEF) 25-75% at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population

    FEF is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF25-75% is defined as the mean forced expiratory flow between the 25% and 75% of the FVC.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52

  23. Change From Baseline in Post-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population

    FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52

  24. Annualized Rate of Loss of Asthma Control (LOAC) Event During The 52-Week Treatment Period: ITT Population

    LOAC was defined as any of the following: \>=6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days; increase in ICS \>=4 times the dose at randomization; use of systemic corticosteroids for \>=3 days; hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of LOAC that occurred during the treatment period divided by the total number of participant-years treated.

    Time frame: Baseline to Week 52

  25. Time to First Severe Exacerbation Event: Kaplan-Meier Estimates During The 52-Week Treatment Period: ITT Population

    The time to first severe exacerbation was defined as follows: date of the first event - randomization date +1. For participants who had no event on or before Visit 18 (Week 52) or last contact date, the time was censored at the date of Visit 18 or the last contact date, whichever was earlier. The median time to first severe exacerbation was not estimated; therefore, the probability of severe exacerbation at Weeks 12, 24, 36, and 52, are presented as the descriptive statistics.

    Time frame: Baseline up to Week 52

  26. Time to First LOAC Event: Kaplan-Meier Estimates During The 52-Week Treatment Period: ITT Population

    The time to first LOAC event was defined as follows: date of the first event - first dose date +1. For participants who had no event on or before last dose date + 14 days or last contact date, the time was censored at the last dose date + 14 days or the last contact date, whichever was earlier.

    Time frame: Baseline up to Week 52

  27. Change From Baseline in ACQ-5 Score at Weeks 2, 4, 8, 12, 36, and 52: ITT Population

    The ACQ-5 has 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 36, and 52

  28. Change From Baseline in Asthma Control Questionnaire 7-item Version (ACQ-7) Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population

    The ACQ-7 has 7 questions, the first 5 questions assess the most common asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze plus short-acting bronchodilator use, and FEV1 (pre-bronchodilator % predicted). Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). Clinic staff scored the FEV1% predicted on a 7-point scale. The questions were equally weighted and the ACQ-7 total score was mean of the scores of all 7 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52

  29. Change From Baseline in Morning Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population

    Morning asthma symptom score was determined using AM (ante meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the night. It ranged from 0 to 4 as: 0= No asthma symptoms, slept through the night, 1= Slept well, but some complaints in the morning, no night time awakenings, 2= Woke up once because of asthma (including early awakening), 3= Woke up several times because of asthma (including early awakening), 4= Bad night, awake most of the night because of asthma.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52

  30. Change From Baseline in Evening Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population

    Evening asthma symptom score was determined using PM (post meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 to 4 as: 0=very well, no asthma symptoms, 1=one episode of wheezing, cough, or breathlessness, 2=more than one episode of wheezing, cough, or breathlessness without interference of normal activities, 3=wheezing, cough, or breathlessness most of the day, which interfered to some extent with normal activities, 4=asthma very bad, unable to carry out daily activities as usual.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52

  31. Change From Baseline in Number of Nocturnal Awakenings Per Night at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population

    Participants recorded every morning on awakening the number of asthma-related nocturnal awakenings requiring use of rescue medication that occurred during the previous night.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52

  32. Change From Baseline in Number of Puffs of Daily Reliever Medication Used Per 24 Hours at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population

    Participants might administered salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication as needed during the study. The number of salbutamol/albuterol or levosalbutamol/levalbuterol inhalations were recorded daily by the participants in an electronic diary/peak expiratory flow (PEF) meter. In the case that Nebulizer solutions were used as an alternative delivery method, the nebulizer dose was converted to number of puffs as per following conversion factor: salbutamol/albuterol nebulizer solution (2.5 mg) corresponds to 4 puffs.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52

  33. Change From Baseline in AQLQ (S) Self-Administered Global Score at Weeks 12, 36, and 52: ITT Population

    The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.

    Time frame: Baseline, Weeks 12, 36, and 52

  34. Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Scores at Weeks 12, 24, 36, and 52: ITT Population

    EQ-5D-5L is a standardized health-related quality of life questionnaire developed by EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. EQ-5D consists of EQ-5D descriptive system and EQ visual analogue scale (VAS). EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state. EQ-5D-5L-VAS records participant's self-rated health on a vertical VAS that allows them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable).

    Time frame: Baseline, Weeks 12, 24, 36, and 52

  35. Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Weeks 12, 24, 36, and 52: ITT Population

    The HADS is a general scale to detect states of anxiety and depression already used and validated in asthma, which includes HADS-A and HADS-D subscales. The instrument is comprised of 14 items: 7 related to anxiety (HADS-A) and 7 to depression (HADS-D). Each item on the questionnaire is scored from 0-3. The anxiety/depression score is the sum of the scores of the 7 related items; one can score between 0 and 21 for either anxiety or depression. And the total score is the sum of the scores of the 14 items ranging from 0 (no symptoms) to 42 (severe symptoms), with higher scores indicating higher anxiety/depression complains.

    Time frame: Baseline, Weeks 12, 24, 36, and 52

  36. Change From Baseline in 22-Item Sino Nasal Outcome Test (SNOT-22) Score at Weeks 12, 24, 36, and 52: ITT Population With Bilateral Nasal Polyposis/Chronic Rhinosinusitis

    The SNOT-22 is a validated measure of health related quality of life in sinonasal disease. It is a 22 item questionnaire with each item assigned a score ranging from 0-5. The total score may range from 0 (no disease) -110 (worst disease), lower scores represent better health related quality of life.

    Time frame: Baseline, Weeks 12, 24, 36, and 52

  37. Change From Baseline in Standardized Rhinoconjunctivitis Quality Of Life Questionnaire, Ages 12+ (RQLQ[S]+12) Score at Weeks 12, 24, 36, and 52: ITT Population With Comorbid Allergic Rhinitis

    RQLQ(S)+12 is a self-administered questionnaire with standardized activities developed to measure health-related quality of life signs and symptoms that are most problematic in those 12 to 75 years of age, as a result of perennial or seasonal allergic rhinitis. There are 28 items on RQLQ(S) in 7 domains: activities (3 items), sleep (3 items), non-nose/eye symptoms (7 items), practical problems (3 items), nasal symptoms (4 items), eye symptoms (4 items) and emotional (4 items). RQLQ(S)+12 responses are based on 7-point likert scale with responses ranging from 0 (not troubled) to 6 (extremely troubled). Individual items within RQLQ(S)+12 are equally weighted. The overall score is calculated as the mean score of all items. Higher scores indicated more health-related quality of life impairment (lower scores better).

    Time frame: Baseline, Weeks 12, 24, 36, and 52

07

Results

Posted Oct 23, 2018

Participant flow

4148 participants were screened from Apr 2015-Sep 2016. 1902 were randomized at 321 centers/22 countries. 2246 were screen failures. 1897 participants were treated; some received a different treatment than that assigned at randomization and for adverse event (AE) analysis were allocated to treatment actually received (see footnotes in below table)

Participant flow — Overall Study
MilestonePlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Started317631321633
Treated315629321632
Completed295586301582
Not completed22452051
Withdrew: Adverse event97112
Withdrew: Poor compliance to protocol1122
Withdrew: Other than specified above12371737

Outcome measures

PrimaryAnnualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: Intent-to-Treat (ITT) Population

A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.

Time frame:
Baseline to Week 52
Reported as:
Number · Exacerbation per participant-year
Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: Intent-to-Treat (ITT) Population
Exacerbation per participant-yearPlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: Intent-to-Treat (ITT) Population0.871 (0.724 to 1.048)0.456 (0.389 to 0.534)0.970 (0.810 to 1.160)0.524 (0.450 to 0.611)
Statistical analysis
  • Placebo (for Dupilumab 300 mg) q2w vs Dupilumab 300 mg q2w · Negative binomial regression model · p = <0.0001 (Hierarchical testing sequence performed continued only when previous outcome measures was statistically significant at 0.05. Threshold for significance at 0.05 level.) · Relative risk: 0.54 · 95% CI 0.43 to 0.68Dupilumab 300 mg q2w vs Placebo (for Dupilumab 300 mg) q2w
  • Placebo (for Dupilumab 200 mg) q2w vs Dupilumab 200 mg q2w · Negative binomial regression model · p = <0.0001 (Threshold for significance at 0.05 level.) · Relative risk: 0.523 · 95% CI 0.413 to 0.662Dupilumab 200 mg q2w vs Placebo (for Dupilumab 200 mg) q2w
PrimaryAbsolute Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12: ITT Population

FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

Time frame:
Baseline, Week 12
Reported as:
Mean · liter
Absolute Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12: ITT Population
literPlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Baseline1.76 ± 0.611.78 ± 0.621.75 ± 0.571.78 ± 0.60
Week 121.92 ± 0.702.07 ± 0.761.93 ± 0.682.09 ± 0.70
Change at Week 120.15 ± 0.360.28 ± 0.450.18 ± 0.390.31 ± 0.43
Statistical analysis
  • Placebo (for Dupilumab 300 mg) q2w vs Dupilumab 300 mg q2w · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Least square (ls) mean difference: 0.13 · 95% CI 0.08 to 0.18Dupilumab 300 mg q2w vs Placebo (for Dupilumab 300 mg) q2w
  • Placebo (for Dupilumab 200 mg) q2w vs Dupilumab 200 mg q2w · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: 0.14 · 95% CI 0.08 to 0.19Dupilumab 200 mg q2w vs Placebo (for Dupilumab 200 mg) q2w
SecondaryPercent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population

FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

Time frame:
Baseline, Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population
percent changePlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population10.16 ± 23.8818.74 ± 30.8611.87 ± 26.4020.89 ± 34.14
Statistical analysis
  • Placebo (for Dupilumab 300 mg) q2w vs Dupilumab 300 mg q2w · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: 9.41 · 95% CI 5.74 to 13.07Dupilumab 300 mg q2w vs Placebo (for Dupilumab 300 mg) q2w
SecondaryAnnualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil >=0.15 Giga/L

A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.

Time frame:
Baseline to Week 52
Reported as:
Number · Exacerbation per participant-year
Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil >=0.15 Giga/L
Exacerbation per participant-yearPlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil >=0.15 Giga/L1.007 (0.814 to 1.245)0.445 (0.368 to 0.538)1.081 (0.879 to 1.329)0.434 (0.359 to 0.525)
Statistical analysis
  • Placebo (for Dupilumab 300 mg) q2w vs Dupilumab 300 mg q2w · Negative binomial regression model · p = <0.0001 (Threshold for significance at 0.05 level.) · Relative risk: 0.402 · 95% CI 0.307 to 0.526Dupilumab 300 mg q2w vs Placebo (for Dupilumab 300 mg) q2w
SecondaryAbsolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.15 Giga/L

FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

Time frame:
Baseline, Week 12
Reported as:
Mean · liter
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.15 Giga/L
literPlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Baseline1.77 ± 0.631.81 ± 0.631.75 ± 0.551.79 ± 0.59
Change at Week 120.17 ± 0.360.34 ± 0.460.21 ± 0.380.35 ± 0.45
Statistical analysis
  • Placebo (for Dupilumab 300 mg) q2w vs Dupilumab 300 mg q2w · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: 0.15 · 95% CI 0.09 to 0.21Dupilumab 300 mg q2w vs Placebo (for Dupilumab 300 mg) q2w
SecondaryAnnualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil >=0.3 Giga/L

A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.

Time frame:
Baseline to Week 52
Reported as:
Number · Exacerbation per participant-year
Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil >=0.3 Giga/L
Exacerbation per participant-yearPlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil >=0.3 Giga/L1.081 (0.846 to 1.382)0.370 (0.289 to 0.475)1.236 (0.972 to 1.571)0.403 (0.317 to 0.512)
Statistical analysis
  • Placebo (for Dupilumab 300 mg) q2w vs Dupilumab 300 mg q2w · Negative binomial regression model · p = <0.0001 (Threshold for significance at 0.05 level.) · Relative risk: 0.326 · 95% CI 0.234 to 0.454Dupilumab 300 mg q2w vs Placebo (for Dupilumab 300 mg) q2w
SecondaryAbsolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.3 Giga/L

FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

Time frame:
Baseline, Week 12
Reported as:
Mean · liter
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.3 Giga/L
literPlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Baseline1.78 ± 0.661.81 ± 0.641.73 ± 0.541.75 ± 0.59
Change at Week 120.19 ± 0.390.39 ± 0.450.20 ± 0.400.43 ± 0.43
Statistical analysis
  • Placebo (for Dupilumab 300 mg) q2w vs Dupilumab 300 mg q2w · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: 0.24 · 95% CI 0.16 to 0.32Dupilumab 300 mg q2w vs Placebo (for Dupilumab 300 mg) q2w
SecondaryAnnualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil <0.3 Giga/L

A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.

Time frame:
Baseline to Week 52
Reported as:
Number · Exacerbation per participant-year
Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil <0.3 Giga/L
Exacerbation per participant-yearPlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil <0.3 Giga/L0.675 (0.515 to 0.884)0.512 (0.418 to 0.628)0.732 (0.562 to 0.954)0.610 (0.502 to 0.742)
Statistical analysis
  • Placebo (for Dupilumab 300 mg) q2w vs Dupilumab 300 mg q2w · Negative binomial regression model · p = 0.2599 (Threshold for significance at 0.05 level.) · Relative risk: 0.834 · 95% CI 0.608 to 1.144Dupilumab 300 mg q2w vs Placebo (for Dupilumab 300 mg) q2w
SecondaryAnnualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With High Dose ICS at Baseline

A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.

Time frame:
Baseline to Week 52
Reported as:
Number · Exacerbation per participant-year
Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With High Dose ICS at Baseline
Exacerbation per participant-yearPlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With High Dose ICS at Baseline1.040 (0.824 to 1.314)0.560 (0.455 to 0.690)1.038 (0.818 to 1.317)0.639 (0.523 to 0.780)
SecondaryAbsolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With High Dose ICS at Baseline

FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

Time frame:
Baseline, Week 12
Reported as:
Mean · liter
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With High Dose ICS at Baseline
literPlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With High Dose ICS at Baseline0.14 ± 0.340.27 ± 0.420.20 ± 0.400.32 ± 0.43
SecondaryChange From Baseline in Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ [S]) Self-Administered Global Score at Week 24: ITT Population

The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.

Time frame:
Baseline, Week 24
Reported as:
Mean · scores on a scale
Change From Baseline in Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ [S]) Self-Administered Global Score at Week 24: ITT Population
scores on a scalePlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Baseline4.26 ± 1.024.31 ± 1.084.30 ± 1.034.28 ± 1.05
Week 245.23 ± 1.075.46 ± 1.125.30 ± 1.155.47 ± 1.09
Change at Week 240.95 ± 1.031.13 ± 1.141.02 ± 1.101.17 ± 1.11
SecondaryChange From Baseline in AQLQ (S) Self- Administered Global Score at Week 24: ITT Population With Baseline Eosinophil >=0.3 Giga/L

The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.

Time frame:
Baseline, Week 24
Reported as:
Mean · scores on a scale
Change From Baseline in AQLQ (S) Self- Administered Global Score at Week 24: ITT Population With Baseline Eosinophil >=0.3 Giga/L
scores on a scalePlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Baseline4.24 ± 0.984.24 ± 1.114.21 ± 0.974.36 ± 1.05
Change at Week 240.97 ± 1.011.39 ± 1.151.02 ± 1.251.30 ± 1.15
SecondaryChange From Baseline in Asthma Control Questionnaire 5-item Version (ACQ-5) Score at Week 24: ITT Population

The ACQ-5 has 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.

Time frame:
Baseline, Week 24
Reported as:
Mean · scores on a scale
Change From Baseline in Asthma Control Questionnaire 5-item Version (ACQ-5) Score at Week 24: ITT Population
scores on a scalePlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Baseline2.71 ± 0.732.76 ± 0.802.77 ± 0.772.77 ± 0.76
Week 241.67 ± 1.061.33 ± 1.051.58 ± 1.081.37 ± 1.10
Change at Week 24-1.06 ± 1.01-1.43 ± 1.05-1.19 ± 1.10-1.38 ± 1.10
SecondaryAnnualized Rate of Severe Exacerbation Events Resulting in Hospitalization or Emergency Room Visit During The 52-Week Treatment Period: ITT Population

A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations (resulted hospitalization or emergency room visit) that occurred during the treatment period divided by the total number of participant-years treated.

Time frame:
Baseline to Week 52
Reported as:
Number · Exacerbation per participant-year
Annualized Rate of Severe Exacerbation Events Resulting in Hospitalization or Emergency Room Visit During The 52-Week Treatment Period: ITT Population
Exacerbation per participant-yearPlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Annualized Rate of Severe Exacerbation Events Resulting in Hospitalization or Emergency Room Visit During The 52-Week Treatment Period: ITT Population0.081 (0.049 to 0.135)0.043 (0.027 to 0.068)0.034 (0.017 to 0.066)0.025 (0.014 to 0.043)
SecondaryAbsolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil <0.3 Giga/L

FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

Time frame:
Baseline, Week 12
Reported as:
Mean · liter
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil <0.3 Giga/L
literPlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil <0.3 Giga/L0.12 ± 0.320.21 ± 0.430.17 ± 0.390.21 ± 0.41
SecondaryPercent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.3 Giga/L

FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

Time frame:
Baseline, Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.3 Giga/L
percent changePlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.3 Giga/L13.40 ± 27.0126.41 ± 33.6913.05 ± 25.2730.58 ± 38.22
SecondaryPercent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With High Dose ICS at Baseline

FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

Time frame:
Baseline, Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With High Dose ICS at Baseline
percent changePlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With High Dose ICS at Baseline8.47 ± 20.9417.99 ± 28.4313.22 ± 26.5223.41 ± 37.26
SecondaryPercent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.15 Giga/L

FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

Time frame:
Baseline, Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.15 Giga/L
percent changePlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.15 Giga/L11.43 ± 24.7122.04 ± 31.9613.49 ± 25.1824.04 ± 35.71
SecondaryAbsolute Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 24, 36, and 52: ITT Population

FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

Time frame:
Baseline, Weeks 2, 4, 8, 24, 36, and 52
Reported as:
Mean · liter
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 24, 36, and 52: ITT Population
literPlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Change at Week 20.08 ± 0.350.22 ± 0.380.10 ± 0.340.25 ± 0.40
Change at Week 40.13 ± 0.350.24 ± 0.400.13 ± 0.340.27 ± 0.41
Change at Week 80.15 ± 0.380.28 ± 0.420.19 ± 0.400.29 ± 0.43
Change at Week 240.13 ± 0.400.31 ± 0.450.19 ± 0.440.30 ± 0.44
Change at Week 360.14 ± 0.410.31 ± 0.480.21 ± 0.420.32 ± 0.45
Change at Week 520.12 ± 0.380.31 ± 0.500.20 ± 0.420.32 ± 0.44
SecondaryPercent Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 24, 36, and 52: ITT Population

FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

Time frame:
Baseline, Weeks 2, 4, 8, 24, 36, and 52
Reported as:
Mean · percent change
Percent Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 24, 36, and 52: ITT Population
percent changePlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Change at Week 25.78 ± 23.3614.32 ± 26.556.60 ± 21.8417.38 ± 30.82
Change at Week 49.61 ± 25.5416.11 ± 28.128.67 ± 23.5518.77 ± 32.73
Change at Week 810.27 ± 25.6018.81 ± 29.8012.24 ± 25.7819.85 ± 33.63
Change at Week 249.42 ± 26.7619.76 ± 30.6412.86 ± 28.1420.75 ± 35.35
Change at Week 3610.57 ± 26.4119.92 ± 32.2613.45 ± 27.6922.08 ± 35.93
Change at Week 528.37 ± 23.5919.96 ± 33.3512.89 ± 27.7021.57 ± 34.08
SecondaryChange From Baseline in Percent Predicted FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population

FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Reported as:
Mean · percent predicted of FEV1
Change From Baseline in Percent Predicted FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
percent predicted of FEV1Placebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Change at Week 22.58 ± 11.367.10 ± 12.283.32 ± 10.988.44 ± 13.20
Change at Week 44.55 ± 11.697.92 ± 12.814.13 ± 11.419.20 ± 14.10
Change at Week 84.93 ± 12.309.27 ± 13.136.08 ± 12.559.70 ± 14.15
Change at Week 125.02 ± 12.109.22 ± 13.875.90 ± 13.0210.28 ± 14.44
Change at Week 244.38 ± 12.859.98 ± 13.946.41 ± 14.0210.14 ± 14.75
Change at Week 365.09 ± 12.9910.12 ± 14.616.82 ± 13.5410.94 ± 15.06
Change at Week 524.25 ± 12.0610.08 ± 14.796.68 ± 13.5611.02 ± 14.59
SecondaryChange From Baseline in Morning (AM)/Evening (PM) Peak Expiratory Flow (PEF) at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population

The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at home (morning and evening) while sitting or standing prior to using any medication (if needed) for asthma.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Reported as:
Mean · liters/min
Change From Baseline in Morning (AM)/Evening (PM) Peak Expiratory Flow (PEF) at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
liters/minPlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
AM: Change at Week 24.19 ± 31.3015.21 ± 39.453.45 ± 28.9514.46 ± 36.29
AM: Change at Week 46.23 ± 42.4221.81 ± 53.855.55 ± 43.6919.67 ± 46.47
AM: Change at Week 87.42 ± 49.3025.70 ± 58.5212.22 ± 50.5023.18 ± 52.65
AM: Change at Week 129.85 ± 50.4027.81 ± 65.3014.23 ± 56.1825.88 ± 57.09
AM: Change at Week 245.55 ± 53.2728.71 ± 69.6415.43 ± 60.8323.74 ± 63.71
AM: Change at Week 363.24 ± 61.6831.19 ± 71.5912.57 ± 61.8823.93 ± 65.04
AM: Change at Week 522.85 ± 64.6029.86 ± 75.4410.99 ± 64.6826.67 ± 71.63
PM: Change at Week 23.33 ± 36.8113.80 ± 40.593.87 ± 33.9811.35 ± 36.10
PM: Change at Week 45.01 ± 45.0917.94 ± 55.302.73 ± 46.8314.90 ± 47.42
PM: Change at Week 82.82 ± 50.1021.06 ± 61.807.68 ± 56.7317.26 ± 53.37
PM: Change at Week 123.24 ± 53.4219.75 ± 68.148.52 ± 56.7418.70 ± 55.60
PM: Change at Week 24-4.89 ± 55.0719.95 ± 71.507.56 ± 63.2515.82 ± 61.91
PM: Change at Week 36-6.75 ± 62.4421.79 ± 75.002.64 ± 65.2114.35 ± 64.66
PM: Change at Week 52-6.43 ± 62.8218.77 ± 77.372.83 ± 67.0115.58 ± 72.51
SecondaryChange From Baseline in Forced Vital Capacity (FVC) at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population

FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC is the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Reported as:
Mean · liter
Change From Baseline in Forced Vital Capacity (FVC) at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
literPlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Change at Week 20.08 ± 0.420.23 ± 0.440.10 ± 0.370.25 ± 0.46
Change at Week 40.12 ± 0.390.26 ± 0.450.12 ± 0.380.27 ± 0.47
Change at Week 80.13 ± 0.410.28 ± 0.450.18 ± 0.420.29 ± 0.50
Change at Week 120.13 ± 0.410.29 ± 0.490.18 ± 0.440.29 ± 0.51
Change at Week 240.11 ± 0.450.29 ± 0.480.18 ± 0.460.29 ± 0.51
Change at Week 360.11 ± 0.450.30 ± 0.520.19 ± 0.470.31 ± 0.52
Change at Week 520.08 ± 0.450.29 ± 0.530.18 ± 0.450.31 ± 0.50
SecondaryChange From Baseline in Forced Expiratory Flow (FEF) 25-75% at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population

FEF is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF25-75% is defined as the mean forced expiratory flow between the 25% and 75% of the FVC.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Reported as:
Mean · liters/sec
Change From Baseline in Forced Expiratory Flow (FEF) 25-75% at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
liters/secPlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Change at Week 20.09 ± 0.400.22 ± 0.470.11 ± 0.440.27 ± 0.48
Change at Week 40.16 ± 0.450.24 ± 0.480.15 ± 0.440.29 ± 0.48
Change at Week 80.18 ± 0.450.29 ± 0.520.20 ± 0.490.32 ± 0.51
Change at Week 120.18 ± 0.460.30 ± 0.530.19 ± 0.500.35 ± 0.53
Change at Week 240.17 ± 0.470.34 ± 0.570.22 ± 0.560.35 ± 0.54
Change at Week 360.18 ± 0.490.35 ± 0.590.22 ± 0.490.36 ± 0.56
Change at Week 520.16 ± 0.500.36 ± 0.630.24 ± 0.550.36 ± 0.55
SecondaryChange From Baseline in Post-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population

FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Reported as:
Mean · liter
Change From Baseline in Post-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
literPlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Change at Week 2-0.07 ± 0.310.10 ± 0.37-0.04 ± 0.330.09 ± 0.34
Change at Week 4-0.02 ± 0.310.10 ± 0.39-0.04 ± 0.360.10 ± 0.36
Change at Week 8-0.02 ± 0.310.12 ± 0.400.03 ± 0.350.11 ± 0.37
Change at Week 12-0.02 ± 0.330.12 ± 0.400.01 ± 0.350.11 ± 0.38
Change at Week 24-0.05 ± 0.360.13 ± 0.43-0.01 ± 0.400.10 ± 0.39
Change at Week 36-0.03 ± 0.340.12 ± 0.440.01 ± 0.380.11 ± 0.39
Change at Week 52-0.08 ± 0.380.12 ± 0.44-0.02 ± 0.390.11 ± 0.40
SecondaryAnnualized Rate of Loss of Asthma Control (LOAC) Event During The 52-Week Treatment Period: ITT Population

LOAC was defined as any of the following: \>=6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days; increase in ICS \>=4 times the dose at randomization; use of systemic corticosteroids for \>=3 days; hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of LOAC that occurred during the treatment period divided by the total number of participant-years treated.

Time frame:
Baseline to Week 52
Reported as:
Number · LOAC per participant-year
Annualized Rate of Loss of Asthma Control (LOAC) Event During The 52-Week Treatment Period: ITT Population
LOAC per participant-yearPlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Annualized Rate of Loss of Asthma Control (LOAC) Event During The 52-Week Treatment Period: ITT Population2.972 (2.573 to 3.432)1.853 (1.654 to 2.076)2.965 (2.572 to 3.420)1.740 (1.554 to 1.947)
SecondaryTime to First Severe Exacerbation Event: Kaplan-Meier Estimates During The 52-Week Treatment Period: ITT Population

The time to first severe exacerbation was defined as follows: date of the first event - randomization date +1. For participants who had no event on or before Visit 18 (Week 52) or last contact date, the time was censored at the date of Visit 18 or the last contact date, whichever was earlier. The median time to first severe exacerbation was not estimated; therefore, the probability of severe exacerbation at Weeks 12, 24, 36, and 52, are presented as the descriptive statistics.

Time frame:
Baseline up to Week 52
Reported as:
Number · probability of severe exacerbation
Time to First Severe Exacerbation Event: Kaplan-Meier Estimates During The 52-Week Treatment Period: ITT Population
probability of severe exacerbationPlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Probability at Week 120.165 (0.127 to 0.209)0.094 (0.073 to 0.119)0.193 (0.152 to 0.238)0.137 (0.112 to 0.166)
Probability at Week 240.275 (0.227 to 0.326)0.177 (0.148 to 0.208)0.297 (0.247 to 0.347)0.211 (0.180 to 0.243)
Probability at Week 360.364 (0.311 to 0.418)0.235 (0.203 to 0.270)0.376 (0.322 to 0.428)0.268 (0.234 to 0.303)
Probability at Week 520.434 (0.378 to 0.489)0.295 (0.259 to 0.331)0.437 (0.382 to 0.491)0.325 (0.288 to 0.362)
SecondaryTime to First LOAC Event: Kaplan-Meier Estimates During The 52-Week Treatment Period: ITT Population

The time to first LOAC event was defined as follows: date of the first event - first dose date +1. For participants who had no event on or before last dose date + 14 days or last contact date, the time was censored at the last dose date + 14 days or the last contact date, whichever was earlier.

Time frame:
Baseline up to Week 52
Reported as:
Median · days
Time to First LOAC Event: Kaplan-Meier Estimates During The 52-Week Treatment Period: ITT Population
daysPlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Time to First LOAC Event: Kaplan-Meier Estimates During The 52-Week Treatment Period: ITT Population110.0 (84.00 to 144.00)230.0 (187.00 to 276.00)102.0 (74.00 to 130.00)264.0 (207.00 to 319.00)
SecondaryChange From Baseline in ACQ-5 Score at Weeks 2, 4, 8, 12, 36, and 52: ITT Population

The ACQ-5 has 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 36, and 52
Reported as:
Mean · scores on a scale
Change From Baseline in ACQ-5 Score at Weeks 2, 4, 8, 12, 36, and 52: ITT Population
scores on a scalePlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Change at Week 2-0.52 ± 0.85-0.88 ± 0.91-0.58 ± 0.97-0.89 ± 0.94
Change at Week 4-0.76 ± 0.90-1.07 ± 0.98-0.77 ± 1.01-1.06 ± 1.01
Change at Week 8-0.94 ± 0.96-1.26 ± 1.03-1.05 ± 1.04-1.24 ± 1.06
Change at Week 12-0.98 ± 1.00-1.33 ± 1.03-1.09 ± 1.09-1.35 ± 1.06
Change at Week 36-1.21 ± 1.01-1.50 ± 1.14-1.22 ± 1.09-1.52 ± 1.09
Change at Week 52-1.07 ± 1.08-1.50 ± 1.05-1.25 ± 1.05-1.50 ± 1.08
SecondaryChange From Baseline in Asthma Control Questionnaire 7-item Version (ACQ-7) Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population

The ACQ-7 has 7 questions, the first 5 questions assess the most common asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze plus short-acting bronchodilator use, and FEV1 (pre-bronchodilator % predicted). Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). Clinic staff scored the FEV1% predicted on a 7-point scale. The questions were equally weighted and the ACQ-7 total score was mean of the scores of all 7 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Reported as:
Mean · scores on a scale
Change From Baseline in Asthma Control Questionnaire 7-item Version (ACQ-7) Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
scores on a scalePlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Change at Week 2-0.46 ± 0.70-0.79 ± 0.77-0.50 ± 0.80-0.82 ± 0.81
Change at Week 4-0.65 ± 0.76-0.94 ± 0.85-0.65 ± 0.85-0.97 ± 0.87
Change at Week 8-0.81 ± 0.80-1.11 ± 0.90-0.90 ± 0.89-1.12 ± 0.92
Change at Week 12-0.85 ± 0.83-1.17 ± 0.90-0.92 ± 0.93-1.20 ± 0.92
Change at Week 24-0.89 ± 0.91-1.25 ± 0.92-1.01 ± 0.96-1.22 ± 0.96
Change at Week 36-1.04 ± 0.84-1.32 ± 1.01-1.05 ± 0.94-1.35 ± 0.95
Change at Week 52-0.91 ± 0.92-1.32 ± 0.91-1.07 ± 0.91-1.34 ± 0.93
SecondaryChange From Baseline in Morning Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population

Morning asthma symptom score was determined using AM (ante meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the night. It ranged from 0 to 4 as: 0= No asthma symptoms, slept through the night, 1= Slept well, but some complaints in the morning, no night time awakenings, 2= Woke up once because of asthma (including early awakening), 3= Woke up several times because of asthma (including early awakening), 4= Bad night, awake most of the night because of asthma.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Reported as:
Mean · scores on a scale
Change From Baseline in Morning Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
scores on a scalePlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Change at Week 2-0.07 ± 0.43-0.18 ± 0.49-0.09 ± 0.49-0.15 ± 0.50
Change at Week 4-0.16 ± 0.59-0.26 ± 0.59-0.16 ± 0.61-0.27 ± 0.64
Change at Week 8-0.26 ± 0.64-0.40 ± 0.68-0.25 ± 0.62-0.37 ± 0.70
Change at Week 12-0.30 ± 0.64-0.45 ± 0.71-0.30 ± 0.69-0.44 ± 0.72
Change at Week 24-0.35 ± 0.69-0.52 ± 0.76-0.36 ± 0.73-0.50 ± 0.73
Change at Week 36-0.38 ± 0.69-0.54 ± 0.81-0.38 ± 0.76-0.56 ± 0.77
Change at Week 52-0.41 ± 0.71-0.55 ± 0.84-0.41 ± 0.78-0.60 ± 0.79
SecondaryChange From Baseline in Evening Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population

Evening asthma symptom score was determined using PM (post meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 to 4 as: 0=very well, no asthma symptoms, 1=one episode of wheezing, cough, or breathlessness, 2=more than one episode of wheezing, cough, or breathlessness without interference of normal activities, 3=wheezing, cough, or breathlessness most of the day, which interfered to some extent with normal activities, 4=asthma very bad, unable to carry out daily activities as usual.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Reported as:
Mean · scores on a scale
Change From Baseline in Evening Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
scores on a scalePlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Change at Week 2-0.05 ± 0.45-0.17 ± 0.48-0.06 ± 0.45-0.16 ± 0.52
Change at Week 4-0.11 ± 0.59-0.27 ± 0.61-0.14 ± 0.58-0.29 ± 0.64
Change at Week 8-0.24 ± 0.64-0.41 ± 0.70-0.22 ± 0.63-0.40 ± 0.70
Change at Week 12-0.26 ± 0.66-0.45 ± 0.72-0.30 ± 0.68-0.46 ± 0.73
Change at Week 24-0.33 ± 0.72-0.52 ± 0.78-0.36 ± 0.72-0.52 ± 0.73
Change at Week 36-0.39 ± 0.73-0.56 ± 0.81-0.39 ± 0.75-0.56 ± 0.80
Change at Week 52-0.41 ± 0.74-0.57 ± 0.84-0.42 ± 0.75-0.61 ± 0.78
SecondaryChange From Baseline in Number of Nocturnal Awakenings Per Night at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population

Participants recorded every morning on awakening the number of asthma-related nocturnal awakenings requiring use of rescue medication that occurred during the previous night.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Reported as:
Mean · number of nocturnal awakenings/night
Change From Baseline in Number of Nocturnal Awakenings Per Night at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
number of nocturnal awakenings/nightPlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Change at Week 2-0.06 ± 0.49-0.15 ± 0.55-0.04 ± 0.62-0.11 ± 0.67
Change at Week 4-0.10 ± 0.61-0.19 ± 0.66-0.11 ± 0.70-0.20 ± 0.67
Change at Week 8-0.18 ± 0.65-0.29 ± 0.72-0.17 ± 0.62-0.24 ± 0.72
Change at Week 12-0.21 ± 0.66-0.33 ± 0.75-0.18 ± 0.67-0.28 ± 0.73
Change at Week 24-0.23 ± 0.78-0.36 ± 0.81-0.26 ± 0.65-0.30 ± 0.73
Change at Week 36-0.25 ± 0.74-0.34 ± 0.81-0.26 ± 0.71-0.36 ± 0.74
Change at Week 52-0.24 ± 0.69-0.35 ± 0.88-0.26 ± 0.74-0.41 ± 0.78
SecondaryChange From Baseline in Number of Puffs of Daily Reliever Medication Used Per 24 Hours at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population

Participants might administered salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication as needed during the study. The number of salbutamol/albuterol or levosalbutamol/levalbuterol inhalations were recorded daily by the participants in an electronic diary/peak expiratory flow (PEF) meter. In the case that Nebulizer solutions were used as an alternative delivery method, the nebulizer dose was converted to number of puffs as per following conversion factor: salbutamol/albuterol nebulizer solution (2.5 mg) corresponds to 4 puffs.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52
Reported as:
Mean · Number of puffs of reliever medication
Change From Baseline in Number of Puffs of Daily Reliever Medication Used Per 24 Hours at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population
Number of puffs of reliever medicationPlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Change at Week 2-0.21 ± 1.55-0.56 ± 1.96-0.10 ± 1.71-0.47 ± 1.91
Change at Week 4-0.26 ± 2.19-0.68 ± 2.61-0.34 ± 3.42-0.73 ± 2.42
Change at Week 8-0.50 ± 2.23-1.02 ± 2.86-0.65 ± 2.96-0.94 ± 2.86
Change at Week 12-0.52 ± 2.28-1.23 ± 3.03-0.89 ± 3.06-1.08 ± 2.72
Change at Week 24-0.77 ± 2.60-1.27 ± 3.05-0.99 ± 3.21-1.15 ± 2.83
Change at Week 36-0.99 ± 2.49-1.30 ± 2.99-1.06 ± 3.57-1.23 ± 3.01
Change at Week 52-0.90 ± 2.58-1.45 ± 3.33-1.12 ± 3.64-1.39 ± 2.97
SecondaryChange From Baseline in AQLQ (S) Self-Administered Global Score at Weeks 12, 36, and 52: ITT Population

The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.

Time frame:
Baseline, Weeks 12, 36, and 52
Reported as:
Mean · scores on a scale
Change From Baseline in AQLQ (S) Self-Administered Global Score at Weeks 12, 36, and 52: ITT Population
scores on a scalePlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Change at Week 120.90 ± 0.971.09 ± 1.030.94 ± 1.011.09 ± 1.09
Change at Week 361.05 ± 1.081.26 ± 1.171.08 ± 1.161.33 ± 1.15
Change at Week 521.00 ± 1.121.28 ± 1.161.02 ± 1.101.34 ± 1.16
SecondaryChange From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Scores at Weeks 12, 24, 36, and 52: ITT Population

EQ-5D-5L is a standardized health-related quality of life questionnaire developed by EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. EQ-5D consists of EQ-5D descriptive system and EQ visual analogue scale (VAS). EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state. EQ-5D-5L-VAS records participant's self-rated health on a vertical VAS that allows them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable).

Time frame:
Baseline, Weeks 12, 24, 36, and 52
Reported as:
Mean · scores on a scale
Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Scores at Weeks 12, 24, 36, and 52: ITT Population
scores on a scalePlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Single Index: Change at Week 120.07 ± 0.170.09 ± 0.180.08 ± 0.180.09 ± 0.18
Single Index: Change at Week 240.07 ± 0.170.09 ± 0.170.08 ± 0.180.08 ± 0.20
Single Index: Change at Week 360.08 ± 0.190.09 ± 0.200.10 ± 0.180.09 ± 0.20
Single Index: Change at Week 520.07 ± 0.200.10 ± 0.190.08 ± 0.190.10 ± 0.20
VAS Score: Change at Week 127.69 ± 17.4311.10 ± 18.906.39 ± 20.429.80 ± 19.56
VAS Score: Change at Week 248.33 ± 17.5811.44 ± 18.488.59 ± 20.379.21 ± 19.61
VAS Score: Change at Week 369.70 ± 18.2411.61 ± 19.099.31 ± 20.0911.41 ± 19.40
VAS Score: Change at Week 528.35 ± 18.5112.98 ± 18.719.52 ± 20.8111.90 ± 19.60
SecondaryChange From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Weeks 12, 24, 36, and 52: ITT Population

The HADS is a general scale to detect states of anxiety and depression already used and validated in asthma, which includes HADS-A and HADS-D subscales. The instrument is comprised of 14 items: 7 related to anxiety (HADS-A) and 7 to depression (HADS-D). Each item on the questionnaire is scored from 0-3. The anxiety/depression score is the sum of the scores of the 7 related items; one can score between 0 and 21 for either anxiety or depression. And the total score is the sum of the scores of the 14 items ranging from 0 (no symptoms) to 42 (severe symptoms), with higher scores indicating higher anxiety/depression complains.

Time frame:
Baseline, Weeks 12, 24, 36, and 52
Reported as:
Mean · scores on a scale
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Weeks 12, 24, 36, and 52: ITT Population
scores on a scalePlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Change at Week 12-2.11 ± 5.29-1.91 ± 5.65-1.55 ± 6.11-1.98 ± 5.89
Change at Week 24-2.17 ± 5.71-1.93 ± 5.97-1.73 ± 6.36-1.88 ± 6.39
Change at Week 36-2.52 ± 5.89-2.02 ± 6.34-2.67 ± 6.80-2.13 ± 6.67
Change at Week 52-2.00 ± 6.29-2.36 ± 6.28-1.86 ± 6.79-2.17 ± 7.04
SecondaryChange From Baseline in 22-Item Sino Nasal Outcome Test (SNOT-22) Score at Weeks 12, 24, 36, and 52: ITT Population With Bilateral Nasal Polyposis/Chronic Rhinosinusitis

The SNOT-22 is a validated measure of health related quality of life in sinonasal disease. It is a 22 item questionnaire with each item assigned a score ranging from 0-5. The total score may range from 0 (no disease) -110 (worst disease), lower scores represent better health related quality of life.

Time frame:
Baseline, Weeks 12, 24, 36, and 52
Reported as:
Mean · scores on a scale
Change From Baseline in 22-Item Sino Nasal Outcome Test (SNOT-22) Score at Weeks 12, 24, 36, and 52: ITT Population With Bilateral Nasal Polyposis/Chronic Rhinosinusitis
scores on a scalePlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Change at Week 12-6.82 ± 17.19-13.55 ± 16.85-11.30 ± 16.11-16.07 ± 20.54
Change at Week 24-7.21 ± 17.10-14.68 ± 18.77-9.55 ± 16.04-17.41 ± 20.81
Change at Week 36-6.10 ± 19.03-15.23 ± 18.20-8.51 ± 20.36-18.86 ± 21.34
Change at Week 52-6.95 ± 17.10-15.78 ± 17.72-9.98 ± 18.01-19.81 ± 22.39
SecondaryChange From Baseline in Standardized Rhinoconjunctivitis Quality Of Life Questionnaire, Ages 12+ (RQLQ[S]+12) Score at Weeks 12, 24, 36, and 52: ITT Population With Comorbid Allergic Rhinitis

RQLQ(S)+12 is a self-administered questionnaire with standardized activities developed to measure health-related quality of life signs and symptoms that are most problematic in those 12 to 75 years of age, as a result of perennial or seasonal allergic rhinitis. There are 28 items on RQLQ(S) in 7 domains: activities (3 items), sleep (3 items), non-nose/eye symptoms (7 items), practical problems (3 items), nasal symptoms (4 items), eye symptoms (4 items) and emotional (4 items). RQLQ(S)+12 responses are based on 7-point likert scale with responses ranging from 0 (not troubled) to 6 (extremely troubled). Individual items within RQLQ(S)+12 are equally weighted. The overall score is calculated as the mean score of all items. Higher scores indicated more health-related quality of life impairment (lower scores better).

Time frame:
Baseline, Weeks 12, 24, 36, and 52
Reported as:
Mean · scores on a scale
Change From Baseline in Standardized Rhinoconjunctivitis Quality Of Life Questionnaire, Ages 12+ (RQLQ[S]+12) Score at Weeks 12, 24, 36, and 52: ITT Population With Comorbid Allergic Rhinitis
scores on a scalePlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Change at Week 12-0.50 ± 0.98-0.70 ± 0.99-0.44 ± 1.05-0.64 ± 1.06
Change at Week 24-0.50 ± 0.92-0.73 ± 1.09-0.54 ± 1.10-0.60 ± 1.10
Change at Week 36-0.56 ± 0.96-0.78 ± 1.15-0.58 ± 1.20-0.75 ± 1.12
Change at Week 52-0.41 ± 0.97-0.90 ± 1.17-0.47 ± 1.33-0.76 ± 1.13

Adverse events

Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 64) or entry in the LTS12551 open-label extension study regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (for Dupilumab 200 mg) q2w3/313 (1%)26/313 (8.3%)185/313 (59.1%)
Dupilumab 200 mg q2w1/631 (0.2%)51/631 (8.1%)363/631 (57.5%)
Placebo (for Dupilumab 300 mg) q2w0/321 (0%)28/321 (8.7%)197/321 (61.4%)
Dupilumab 300 mg q2w5/632 (0.8%)56/632 (8.9%)378/632 (59.8%)
Most frequent serious events
Showing 10 of 148
Most frequent serious events
EventPlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
AsthmaRespiratory, thoracic and mediastinal disorders10/31311/6315/3217/632
PneumoniaInfections and infestations0/3130/6312/3214/632
OsteoarthritisMusculoskeletal and connective tissue disorders1/3130/6312/3212/632
Road traffic accidentInjury, poisoning and procedural complications1/3130/6312/3210/632
Atypical pneumoniaInfections and infestations1/3130/6310/3210/632
Capnocytophaga infectionInfections and infestations1/3130/6310/3210/632
Hepatitis CInfections and infestations1/3130/6310/3210/632
Pyelonephritis chronicInfections and infestations1/3130/6310/3210/632
Anaplastic thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/3130/6310/3210/632
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/3130/6311/3210/632
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlacebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2w
Viral upper respiratory tract infectionInfections and infestations60/313121/63164/321112/632
Injection site erythemaGeneral disorders13/31376/63122/32198/632
BronchitisInfections and infestations47/31373/63143/32170/632
Upper respiratory tract infectionInfections and infestations37/31370/63148/32177/632
InfluenzaInfections and infestations29/31336/63122/32138/632
SinusitisInfections and infestations27/31336/63129/32126/632
HeadacheNervous system disorders26/31347/63125/32140/632
Injection site oedemaGeneral disorders2/31323/6315/32140/632
Urinary tract infectionInfections and infestations17/31317/63112/32120/632
Accidental overdoseInjury, poisoning and procedural complications16/31331/63116/32134/632

Baseline characteristics

Analysis was performed on all randomized participants.

Age, Continuous
Age, Continuous(years)Placebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2wTotal
Mean48.2 ± 15.647.9 ± 15.348.2 ± 14.747.7 ± 15.647.9 ± 15.3
Age, Customized
Age, Customized(Participants)Placebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2wTotal
Adolescents (12-17 years)21341834107
Adults (18-64 years)2535122635161544
From 65-84 years43854083251
Sex: Female, Male
Sex: Female, Male(Participants)Placebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2wTotal
Female1983872183941197
Male119244103239705
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2wTotal
Hispanic or Latino8117179159490
Not Hispanic or Latino2364602424741412
Unknown or Not Reported00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2wTotal
Caucasian/White2655102735291577
Black/of African descent1433122180
Asian/Oriental33783379223
American Indian or Alaska Native10001
Native Hawaiian or Other Pacific Islander01001
Other493420
Blood Eosinophil Group
Blood Eosinophil Group(Participants)Placebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2wTotal
<0.15 Giga/L8519383181542
>=0.15 - <0.3 Giga/L8417395175527
>=0.3 Giga/L148264142277831
ICS Dose Level
ICS Dose Level(Participants)Placebo (for Dupilumab 200 mg) q2wDupilumab 200 mg q2wPlacebo (for Dupilumab 300 mg) q2wDupilumab 300 mg q2wTotal
High172317167323979
Medium144310151303908
Low143715
08

Study locations

389 sites
  • Investigational Site Number 840047
    Birmingham, Alabama 35209, United States
  • Investigational Site Number 840056
    Flagstaff, Arizona 86001, United States
  • Investigational Site Number 840099
    Gilbert, Arizona 85234, United States
  • Investigational Site Number 840087
    Scottsdale, Arizona 85251, United States
  • Investigational Site Number 840132
    Little Rock, Arkansas 72209, United States
  • Investigational Site Number 840109
    Bakersfield, California 93301, United States
  • Investigational Site Number 840052
    Costa Mesa, California 92626, United States
  • Investigational Site Number 840116
    Fresno, California 93720, United States
  • Investigational Site Number 840045
    Long Beach, California 90720, United States
  • Investigational Site Number 840011
    Los Angeles, California 90025, United States
  • Investigational Site Number 840061
    Los Angeles, California 90048, United States
  • Investigational Site Number 840097
    Los Angeles, California 90064, United States
  • Investigational Site Number 840019
    Mission Viejo, California 92691, United States
  • Investigational Site Number 840125
    Newport Beach, California 92663, United States
  • Investigational Site Number 840041
    North Hollywood, California 91606, United States
  • Investigational Site Number 840036
    Redwood City, California 94063, United States
  • Investigational Site Number 840020
    Rolling Hills Estates, California 90274, United States
  • Investigational Site Number 840074
    Roseville, California 95661, United States
  • Investigational Site Number 840021
    San Jose, California 95117, United States
  • Investigational Site Number 840004
    Centennial, Colorado 80112, United States
  • Investigational Site Number 840025
    Colorado Springs, Colorado 80907, United States
  • Investigational Site Number 840034
    Denver, Colorado 80230, United States
  • Investigational Site Number 840130
    Denver, Colorado 80246, United States
  • Investigational Site Number 840102
    New Haven, Connecticut 06504, United States
  • Investigational Site Number 840037
    Aventura, Florida 33180, United States
  • Investigational Site Number 840018
    Boynton Beach, Florida 33472, United States
  • Investigational Site Number 840105
    Brandon, Florida 33511, United States
  • Investigational Site Number 840092
    Clearwater, Florida 33765, United States
  • Investigational Site Number 840122
    Hialeah, Florida 33012, United States
  • Investigational Site Number 840053
    Loxahatchee Groves, Florida 33470, United States
  • Investigational Site Number 840069
    Miami, Florida 33173, United States
  • Investigational Site Number 840123
    Ocala, Florida 34471, United States
  • Investigational Site Number 840071
    Ocala, Florida 34474, United States
  • Investigational Site Number 840115
    Ocoee, Florida 34761, United States
  • Investigational Site Number 840055
    Sarasota, Florida 34239, United States
  • Investigational Site Number 840114
    South Miami, Florida 33143, United States
  • Investigational Site Number 840048
    Tampa, Florida 33612, United States
  • Investigational Site Number 840084
    Gainesville, Georgia 30506, United States
  • Investigational Site Number 840044
    Savannah, Georgia 31406, United States
  • Investigational Site Number 840079
    Twin Falls, Idaho 83301, United States
  • Investigational Site Number 840101
    Chicago, Illinois 60611, United States
  • Investigational Site Number 840015
    River Forest, Illinois 60305, United States
  • Investigational Site Number 840089
    Iowa City, Iowa 52242, United States
  • Investigational Site Number 840032
    Fort Mitchell, Kentucky 41017, United States
  • Investigational Site Number 840009
    Owensboro, Kentucky 42303, United States
  • Investigational Site Number 840064
    Bangor, Maine 04401, United States
  • Investigational Site Number 840080
    Baltimore, Maryland 21237, United States
  • Investigational Site Number 840017
    Chevy Chase, Maryland 20815, United States
  • Investigational Site Number 840073
    Gaithersburg, Maryland 20878, United States
  • Investigational Site Number 840127
    White Marsh, Maryland 21162, United States
  • Investigational Site Number 840014
    North Dartmouth, Massachusetts 02747, United States
  • Investigational Site Number 840005
    Minneapolis, Minnesota 55402, United States
  • Investigational Site Number 840013
    Kansas City, Missouri 64111, United States
  • Investigational Site Number 840002
    Saint Louis, Missouri 63141, United States
  • Investigational Site Number 840093
    Saint Louis, Missouri 63141, United States
  • Investigational Site Number 840026
    Missoula, Montana 59808, United States
  • Investigational Site Number 840078
    Omaha, Nebraska 68131, United States
  • Investigational Site Number 840003
    Papillion, Nebraska 27103, United States
  • Investigational Site Number 840111
    Brick, New Jersey 08723, United States
  • Investigational Site Number 840068
    Ocean City, New Jersey 07712, United States
  • Investigational Site Number 840016
    Princeton, New Jersey 08540, United States
  • Investigational Site Number 840096
    Toms River, New Jersey 08775, United States
  • Investigational Site Number 840031
    Bronx, New York 10457, United States
  • Investigational Site Number 840106
    Jamaica, New York 11435, United States
  • Investigational Site Number 840065
    New York, New York 10029, United States
  • Investigational Site Number 840076
    Rochester, New York 14642, United States
  • Investigational Site Number 840126
    Charlotte, North Carolina 28226, United States
  • Investigational Site Number 840083
    Charlotte, North Carolina 28277, United States
  • Investigational Site Number 840108
    Durham, North Carolina 27705, United States
  • Investigational Site Number 840107
    Greensboro, North Carolina 27403, United States
  • Investigational Site Number 840007
    High Point, North Carolina 27262, United States
  • Investigational Site Number 840046
    Cincinnati, Ohio 45241, United States
  • Investigational Site Number 840049
    Middleburg Heights, Ohio 44130, United States
  • Investigational Site Number 840042
    Toledo, Ohio 43617, United States
  • Investigational Site Number 840112
    Edmond, Oklahoma 73034, United States
  • Investigational Site Number 840121
    Oklahoma City, Oklahoma 73103, United States
  • Investigational Site Number 840104
    Tulsa, Oklahoma 74136, United States
  • Investigational Site Number 840040
    Clackamas, Oregon 97015, United States
  • Investigational Site Number 840039
    Medford, Oregon 97504, United States
  • Investigational Site Number 840001
    Portland, Oregon 97223, United States
  • Investigational Site Number 840085
    Hershey, Pennsylvania 17033, United States
  • Investigational Site Number 840081
    Philadelphia, Pennsylvania 19102, United States
  • Investigational Site Number 840010
    Philadelphia, Pennsylvania 19107, United States
  • Investigational Site Number 840067
    Philadelphia, Pennsylvania 19140, United States
  • Investigational Site Number 840028
    Pittsburgh, Pennsylvania 15213, United States
  • Investigational Site Number 840091
    Pittsburgh, Pennsylvania 15241, United States
  • Investigational Site Number 840029
    Lincoln, Rhode Island 02286, United States
  • Investigational Site Number 840082
    Charleston, South Carolina 29407, United States
  • Investigational Site Number 840117
    Greenville, South Carolina 29607, United States
  • Investigational Site Number 840100
    Greer, South Carolina 29651, United States
  • Investigational Site Number 840054
    Spartanburg, South Carolina 29303, United States
  • Investigational Site Number 840062
    Amarillo, Texas 79106, United States
  • Investigational Site Number 840098
    Austin, Texas 78759, United States
  • Investigational Site Number 840038
    Boerne, Texas 78006, United States
  • Investigational Site Number 840124
    Cypress, Texas 77429, United States
  • Investigational Site Number 840008
    Dallas, Texas 75231, United States
  • Investigational Site Number 840094
    Dallas, Texas 75246, United States
  • Investigational Site Number 840023
    El Paso, Texas 79903, United States
  • Investigational Site Number 840022
    Fort Worth, Texas 76109, United States
  • Investigational Site Number 840027
    Fort Worth, Texas 76244, United States

Showing the first 100 of 389 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018 Jun 28;378(26):2486-2496. doi: 10.1056/NEJMoa1804092. Epub 2018 May 21. PubMed 29782217 ↗
  • Bourdin A, Virchow JC, Papi A, Lugogo NL, Bardin P, Antila M, Halpin DMG, Daizadeh N, Djandji M, Ortiz B, Jacob-Nara JA, Gall R, Deniz Y, Rowe PJ. Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline. Respir Med. 2022 Oct;202:106938. doi: 10.1016/j.rmed.2022.106938. Epub 2022 Aug 11. PubMed 36087550 ↗
  • Papi A, Corren J, Castro M, Domingo C, Rogers L, Chapman KR, Jackson DJ, Daizadeh N, Pandit-Abid N, Gall R, Jacob-Nara JA, Rowe PJ, Deniz Y, Ortiz B. Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthma. Allergy. 2023 Jan;78(1):233-243. doi: 10.1111/all.15456. Epub 2022 Aug 9. PubMed 35899469 ↗
  • Wechsler ME, Klion AD, Paggiaro P, Nair P, Staumont-Salle D, Radwan A, Johnson RR, Kapoor U, Khokhar FA, Daizadeh N, Chen Z, Laws E, Ortiz B, Jacob-Nara JA, Mannent LP, Rowe PJ, Deniz Y. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis. J Allergy Clin Immunol Pract. 2022 Oct;10(10):2695-2709. doi: 10.1016/j.jaip.2022.05.019. Epub 2022 May 28. PubMed 35636689 ↗
  • Rabe KF, Pavord ID, Castro M, Wechsler ME, Daizadeh N, Kapoor U, Ortiz B, Radwan A, Johnson RR, Rowe PJ, Deniz Y, Jacob-Nara JA. Dupilumab efficacy and safety in patients with asthma and blood eosinophils >/=500 cells.microL-1. Eur Respir J. 2022 Jun 23;59(6):2102577. doi: 10.1183/13993003.02577-2021. Print 2022 Jun. PubMed 35487538 ↗
  • Rhee CK, Park JW, Park HW, Cho YS. Effect of Dupilumab in Korean Patients With Uncontrolled Moderate-to-Severe Asthma: A LIBERTY ASTHMA QUEST Sub-analysis. Allergy Asthma Immunol Res. 2022 Mar;14(2):182-195. doi: 10.4168/aair.2022.14.2.182. PubMed 35255536 ↗
  • Geng B, Bachert C, Busse WW, Gevaert P, Lee SE, Niederman MS, Chen Z, Lu X, Khokhar FA, Kapoor U, Pandit-Abid N, Jacob-Nara JA, Rowe PJ, Deniz Y, Ortiz B. Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory Studies. J Allergy Clin Immunol Pract. 2022 Mar;10(3):732-741. doi: 10.1016/j.jaip.2021.12.006. Epub 2021 Dec 22. PubMed 34954123 ↗
  • Tohda Y, Matsumoto H, Miyata M, Taguchi Y, Ueyama M, Joulain F, Arakawa I. Cost-effectiveness analysis of dupilumab among patients with oral corticosteroid-dependent uncontrolled severe asthma in Japan. J Asthma. 2022 Nov;59(11):2162-2173. doi: 10.1080/02770903.2021.1996596. Epub 2021 Dec 8. PubMed 34752208 ↗
  • Busse WW, Paggiaro P, Munoz X, Casale TB, Castro M, Canonica GW, Douglass JA, Tohda Y, Daizadeh N, Ortiz B, Pandit-Abid N. Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma. Eur Respir J. 2021 Oct 7;58(4):2004605. doi: 10.1183/13993003.04605-2020. Print 2021 Oct. PubMed 34326187 ↗
  • Corren J, Katelaris CH, Castro M, Maspero JF, Ford LB, Halpin DMG, Rice MS, Radwan A, Deniz Y, Rowe PJ, Teper A, Djandji M. Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma. Eur Respir J. 2021 Oct 28;58(4):2004498. doi: 10.1183/13993003.04498-2020. Print 2021 Oct. PubMed 34266940 ↗
  • Busse WW, Wenzel SE, Casale TB, FitzGerald JM, Rice MS, Daizadeh N, Deniz Y, Patel N, Harel S, Rowe PJ, Graham NMH, O'Riordan T, Pavord ID. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Lancet Respir Med. 2021 Oct;9(10):1165-1173. doi: 10.1016/S2213-2600(21)00124-7. Epub 2021 Jun 25. PubMed 34181876 ↗
  • Hamilton JD, Harel S, Swanson BN, Brian W, Chen Z, Rice MS, Amin N, Ardeleanu M, Radin A, Shumel B, Ruddy M, Patel N, Pirozzi G, Mannent L, Graham NMH. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy. 2021 Jul;51(7):915-931. doi: 10.1111/cea.13954. Epub 2021 Jun 26. PubMed 34037993 ↗
  • Maspero JF, FitzGerald JM, Pavord ID, Rice MS, Maroni J, Rowe PJ, Pirozzi G, Amin N, Ruddy M, Graham NMH, Teper A, Hardin M. Dupilumab efficacy in adolescents with uncontrolled, moderate-to-severe asthma: LIBERTY ASTHMA QUEST. Allergy. 2021 Aug;76(8):2621-2624. doi: 10.1111/all.14872. Epub 2021 May 10. No abstract available. PubMed 33905544 ↗
  • Bansal A, Simpson EL, Paller AS, Siegfried EC, Blauvelt A, de Bruin-Weller M, Corren J, Sher L, Guttman-Yassky E, Chen Z, Daizadeh N, Kamal MA, Shumel B, Mina-Osorio P, Mannent L, Patel N, Graham NMH, Khokhar FA, Ardeleanu M. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma. Am J Clin Dermatol. 2021 Jan;22(1):101-115. doi: 10.1007/s40257-020-00577-1. PubMed 33481203 ↗
  • Bourdin A, Papi AA, Corren J, Virchow JC, Rice MS, Deniz Y, Djandji M, Rowe P, Pavord ID. Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline. Allergy. 2021 Jan;76(1):269-280. doi: 10.1111/all.14611. Epub 2020 Oct 21. PubMed 33010038 ↗
  • Tohda Y, Nakamura Y, Fujisawa T, Ebisawa M, Arima K, Miyata M, Takahashi Y, Rice MS, Deniz Y, Rowe P, Patel N, Graham NMH, Teper A. Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study. Allergol Int. 2020 Oct;69(4):578-587. doi: 10.1016/j.alit.2020.04.002. Epub 2020 May 20. PubMed 32444306 ↗
  • Corren J, Castro M, O'Riordan T, Hanania NA, Pavord ID, Quirce S, Chipps BE, Wenzel SE, Thangavelu K, Rice MS, Harel S, Jagerschmidt A, Khan AH, Kamat S, Maroni J, Rowe P, Lu Y, Amin N, Pirozzi G, Ruddy M, Graham NMH, Teper A. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. J Allergy Clin Immunol Pract. 2020 Feb;8(2):516-526. doi: 10.1016/j.jaip.2019.08.050. Epub 2019 Sep 12. PubMed 31521831 ↗
  • Maspero JF, Katelaris CH, Busse WW, Castro M, Corren J, Chipps BE, Peters AT, Pavord ID, Ford LB, Sher L, Rabe KF, Rice MS, Rowe P, Lu Y, Harel S, Jagerschmidt A, Khan AH, Kamat S, Pirozzi G, Amin N, Ruddy M, Graham NMH, Mannent LP, Teper A. Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis. J Allergy Clin Immunol Pract. 2020 Feb;8(2):527-539.e9. doi: 10.1016/j.jaip.2019.07.016. Epub 2019 Jul 24. PubMed 31351189 ↗
  • Corren J, Castro M, Chanez P, Fabbri L, Joish VN, Amin N, Graham NMH, Mastey V, Abbe A, Taniou C, Mahajan P, Teper A, Pirozzi G, Eckert L. Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. Ann Allergy Asthma Immunol. 2019 Jan;122(1):41-49.e2. doi: 10.1016/j.anai.2018.08.005. Epub 2018 Aug 21. PubMed 30138668 ↗
  • Busse WW, Maspero JF, Rabe KF, Papi A, Wenzel SE, Ford LB, Pavord ID, Zhang B, Staudinger H, Pirozzi G, Amin N, Akinlade B, Eckert L, Chao J, Graham NMH, Teper A. Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma. Adv Ther. 2018 May;35(5):737-748. doi: 10.1007/s12325-018-0702-4. Epub 2018 May 3. PubMed 29725983 ↗
  • Weinstein SF, Katial R, Jayawardena S, Pirozzi G, Staudinger H, Eckert L, Joish VN, Amin N, Maroni J, Rowe P, Graham NMH, Teper A. Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma. J Allergy Clin Immunol. 2018 Jul;142(1):171-177.e1. doi: 10.1016/j.jaci.2017.11.051. Epub 2018 Jan 31. PubMed 29355679 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2015, a primary completion of Jul 2017 and a completion of Nov 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2018, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2015
First posted
Apr 13, 2015
Start
Apr 27, 2015
Primary completionActual
Jul 29, 2017
CompletionActual
Nov 23, 2017
Results first posted
Oct 23, 2018
Last update
Oct 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02414854
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Apr 13, 2015
Start date
Apr 27, 2015
Primary completion
Jul 29, 2017
Completion
Nov 23, 2017
Results posted
Oct 23, 2018
Last update
Oct 23, 2018

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion